

Thomas Weber, MD

Markus Weber, MD

Prof. Dr. Weber is Professor of Neurology at the University of Basel and serves as chief of the Neuromuscular Diseases Unit/ ALS Clinic at the Kantonsspital St.Gallen in Switzerland. He received his medical degree from the University of Bonn in Germany and Diploma in Clinical Neurology from the University of London, Queen Square. Following completion of his residency at various academic hospitals in Germany and clinical fellowship in neuromuscular disorders at the University of British Columbia in Vancouver, Canada (1997-2000) he founded the Neuromuscular Diseases Center/ALS Clinic in St.Gallen Switzerland and the ALS Clinic at the University of Basel.

His main research interests cover outcome measures, clinical neurophysiology, trial designs and cannabinoid research. His work was crucial in developing a motor unit estimation technique called MUNIX as a biomarker for ALS trials. In collaboration with the ETH Zürich the first cannabinoid type 2 radioligand has been developed, which is now available for clinical use. Prof. Weber has participated in several EU-funded projects (JPND, eRare) and has received numerous grants from national funding bodies and various foundations. He has published well over 150 peer-review publications and book chapters. He has also served on many scientific advisory boards for various biotech companies. Prof. Weber is a member of the ENCALS executive committee and research committee of the European Neuromuscular Center (ENMC) He has previously served as co-chair of the European Academy of Neurology scientific panel on ALS and FTD.